MetaCap

DiaMedica Therapeutics (DMAC) vs Lyell Immunopharma (LYEL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

DiaMedica Therapeutics (DMAC) has outperformed Lyell Immunopharma (LYEL) over the past year, gaining 8.1% versus a loss of 27.9%. Over five years, DMAC leads with a +118.8% price change compared with -92.6% for LYEL. DiaMedica Therapeutics is the larger company by market cap ($445.1 million vs $441.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DMAC+8.13%LYEL-27.86%
+110%+21%-69%
Nov 21, 20251 yearNov 20, 2026
DMAC+115.97%LYEL-93.62%
+158%+25%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DMAC versus LYEL key metrics
MetricDMACLYEL
Share price$8.25$13.80
Market cap$445.15M$441.82M
1-day change+2.87%+1.62%
YTD return+3.64%-55.17%
1-year return+8.13%-27.86%
5-year return+118.83%-92.59%
EPS (TTM)$-0.75$-12.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$36.00K
Revenue growth (YoY)—-40.98%
Net income (latest FY)$-32.77M$-274.45M
Operating margin—-748344.44%
Net margin—-762355.56%
52-week high$11.00$45.00
52-week low$5.25$7.20
Distance from 52-week high-25.00%-69.33%
Analyst consensusstrong_buybuy
Avg. price target upside+96.97%+172.68%
Average volume210.46K174.76K
Shares outstanding53.96M32.02M
Employees35161
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DMAC has outperformed LYEL by 36.0 percentage points over the past year.

About DiaMedica Therapeutics

DMAC stock →

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.

Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees

About Lyell Immunopharma

LYEL stock →

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

DMAC vs LYEL FAQ

Which is bigger, DiaMedica Therapeutics or Lyell Immunopharma?

DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $445.15M compared with $441.82M for Lyell Immunopharma (LYEL).

Which stock has performed better over the past year, DMAC or LYEL?

DMAC returned +8.13% over the past 12 months, compared with -27.86% for LYEL (price return, excluding dividends). Past performance does not predict future results.

Are DiaMedica Therapeutics and Lyell Immunopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons